The Role Of Fibrosis And Immune Inflammation In Depression In Patients With Ischemic Stroke
Life Sciences-Health
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.SP23.L51-56Keywords:
Post-Stroke Depression, Fibrosis Markers, CytokinesAbstract
Nowadays, Stroke is regarded as the second major cause of death and the third major cause of morbidity globally. The ischemic stroke (IS) is among the most fatal kind of strokes. Thus, due to the importance of this subject, this article aims to analyze the role of fibrosis markers (matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinases-1), cytokines (tumor necrosis factor-α, interferon-γ, monocytic chemoattractant protein-1) in the development of post-stroke depression in elderly patients with arterial hypertension (AH). To that end, the study included 114 elderly patients with the first acute ischemic stroke; the average age of the patients was 68 ± 7 years. The control group consisted of 20 older people without hypertension and a history of stroke. The level of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) was determined by ELISA (ELISA Kit, USA); the level of tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), monocytic chemoattractant protein-1 (MCP-1) - JSC "Vector-Best", Russia. After 3 months of observation of patients, post-stroke depression (PD) developed in 50 people. (43.8%). Patients who developed PD were significantly older (9.4%, p <0.05), a higher body mass index by 12.2% (p <0.05), a glycemic level by 16.1% (p <0, 05), triglycerides by 14.0% (p <0.05), LDL by 12.8% (p <0.05) than in patients without depression. Patients with ischemic stroke and PD had higher levels of cytokines - TNF-α by 23.8% (p <0.01), INF-γ by 17.5% (p <0.01), MCP-1 by 17, 6% (p <0.01), the level of MMP-9 was higher by 15.3% (p <0.05), TIMP-1 - by 11.4% (p <0.05). Thus, in elderly patients with hypertension with ischemic stroke, the level of fibrosis and inflammation markers may have a prognostic value in developing post-stroke depression. Hence, this article could greatly contribute to the alleviation of depression in patients with ischemic stroke.
References
Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020-35. doi: 10.1161/STR.0000000000000074, PMID 26123479.
Maksimova MYu, Khokhlova TYu, Suanova ET. Post-stroke depression as a frequent medical and social problem. J Neurol Psychiatry S.S. Korsakov. 2016;116(3):96-103.
Shi Y, Yang D, Zeng Y, Wu W. Risk factors for post-stroke depression: a meta-analysis. Front Aging Neurosci. 2017 Jul 11;9:218. doi: 10.3389/fnagi.2017.00218, PMID 28744213.
Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2018 Apr 1;184:131-44. doi: 10.1016/j.pharmthera.2017.11.005, PMID 29128343.
Maida CD, Norrito RL, Daidone M, Tuttolomondo A, Pinto A. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches. Int J Mol Sci. 2020 Jan;21(18):6454. doi: 10.3390/ijms21186454, PMID 32899616.
Feng C, Fang M, Liu XY. The neurobiological pathogenesis of poststroke depression. ScientificWorldJournal. 2014 Oct;2014:521349. doi: 10.1155/2014/521349, PMID 24744682.
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019 Oct 1;81:24-40. doi: 10.1016/j.bbi.2019.06.015, PMID 31195092.
Arora P, Sagar R, Mehta M, Pallavi P, Sharma S, Mukhopadhyay AK et al. Serum S100B levels in patients with depression. Indian J Psychiatry. 2019 Jan;61(1):70-6. doi: 10.4103/psychiatry.IndianJPsychiatry_391_16, PMID 30745657.
Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S et al. Social stress induces neurovascular pathology promoting depression. Nat Neurosci. 2017 Dec;20(12):1752-60. doi: 10.1038/s41593-017-0010-3, PMID 29184215.
Levada OA, Troyan AS. Poststroke depression biomarkers: a narrative review. Front Neurol. 2018 Jul 16;9:577. doi: 10.3389/fneur.2018.00577, PMID 30061860.
Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014 Feb;71(4):659-72. doi: 10.1007/s00018-013-1457-3, PMID 23982756.
Osipova OA, Gosteva EV, Chefranova ZY, Zhernakova NI, Lykov YA, Avdeeva IV. Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease. Cardiovasc Ther Prev. 2020 Nov 14;19(5):2651. doi: 10.15829/1728-8800-2020-2651.
Ge J, Li R, Yuan P, Che B, Bu X, Shao H et al. Serum tissue inhibitor of metalloproteinase-1 and risk of cognitive impairment after acute ischaemic stroke. J Cell Mol Med. 2020 Jul;24(13):7470-8. doi: 10.1111/jcmm.15369, PMID 32431079.
Zhong C, Wang G, Xu T, Zhu Z, Guo D, Zheng X et al. Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke. Neurology. 2019 Oct 29;93(18):e1675-85. doi: 10.1212/WNL.0000000000008389, PMID 31551260.
Kim JW, Park MS, Kim JT, Kang HJ, Bae KY, Kim SW et al. The impact of tumor necrosis factor-α and interleukin-1β levels and polymorphisms on long-term stroke outcomes. Eur Neurol. 2018;79(1-2):38-44. doi: 10.1159/000484599, PMID 29161722.
Pluta R, Januszewski S, Czuczwar SJ. Neuroinflammation in post-ischemic neurodegeneration of the brain: friend, foe, or both? Int J Mol Sci. 2021 Jan;22(9):4405. doi: 10.3390/ijms22094405, PMID 33922467.
Fatkhullina AR, Peshkova IO, Koltsova EK. The role of cytokines in the development of atherosclerosis. Biochemistry (Mosc). 2016 Nov;81(11):1358-70. doi: 10.1134/S0006297916110134, PMID 27914461.
Folsom AR, Gottesman RF, Appiah D, Shahar E, Mosley TH. Plasma d-dimer and incident ischemic stroke and coronary heart disease: the atherosclerosis risk in communities study. Stroke. 2016 Jan;47(1):18-23. doi: 10.1161/STROKEAHA.115.011035, PMID 26556822.
Mosarrezaii A, Amiri‐Nikpour MR, Mehryar HR, Choobi Anzali B, Nourooz‐Zadeh S, Babaei S et al. Investigating the relationship between interleukin‐6 serum levels and outcome in acute ischemic CVA. Brain Behav. 2020 Aug;10(8):e01668. doi: 10.1002/brb3.1668, PMID 32583980.
Amruta N, Rahman AA, Pinteaux E, Bix G. Neuroinflammation and fibrosis in stroke: the good, the bad and the ugly. J Neuroimmunol. 2020 Sep 15;346:577318. doi: 10.1016/j.jneuroim.2020.577318.
Kim JY, Park J, Chang JY, Kim SH, Lee JE. Inflammation after ischemic stroke: the role of leukocytes and glial cells. Exp Neurobiol. 2016 Oct;25(5):241-51. doi: 10.5607/en.2016.25.5.241, PMID 27790058.
Qin X, Akter F, Qin L, Cheng J, Guo M, Yao S et al. Adaptive immunity regulation and cerebral ischemia. Front Immunol. 2020 May 12;11:689. doi: 10.3389/fimmu.2020.00689, PMID 32477327.
Chang JJ, Stanfill A, Pourmotabbed T. The role of matrix metalloproteinase polymorphisms in ischemic stroke. Int J Mol Sci. 2016 Aug;17(8):1323. doi: 10.3390/ijms17081323, PMID 27529234.
Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis. 2011 Jan 1;20(1):47-54. doi: 10.1016/j.jstrokecerebrovasdis.2009.10.008, PMID 21044610.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Olga A. Osipova, Elena V. Gosteva, Nikolai I. Kluishnikov, Elena V. Kaliuzhnaya, Alexey A. Shabalin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
